JCR Pharmaceuticals announced its development plan in Japan for givinostat, a treatment for Duchenne muscular dystrophy (DMD), following consultation with the Pharmaceuticals and Medical Devices Agency (PMDA). Based… read more.
Merck BioPharma K.K., the Japanese subsidiary of Merck KGaA, began participant registration for a Phase III trial evaluating the efficacy and safety of fixed-dose combinations of follitropin alfa… read more.
The MHRA has approved Romvimza (vimseltinib ) to treat adult patients with tenosynovial giant cell tumour (TGCT) when it impacts movement or where surgery is not an option. TGCT (Giant cell… read more.
Royal Philips announced FDA 510(k) clearance of its next-generation reusable Philips SpO₂ clip sensor, reinforcing the company’s ongoing commitment to providing clinicians with trusted oxygen saturation measurements that… read more.
Keenova Therapeutics plc announced the publication of a new manuscript examining whether baseline penile pain influences treatment outcomes in men with Peyronie’s disease treated with Xiaflex (collagenase clostridium… read more.
Bristol Myers Squibb announced that the FDA has approved ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple… read more.
Daiichi Sankyo and AstraZeneca announced that Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in China for the first-line treatment of adult patients with unresectable or… read more.
10 August 2026 – Kura Oncology, Inc. announced the publication of a manuscript in Blood, the flagship journal of the American Society of Hematology, detailing the discovery and… read more.
4 August 2026 – GE HealthCare announced the introduction of the Logiq e family, featuring Logiq e Xi and Logiq e Si, two compact laptop ultrasound systems designed… read more.
Abbott announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health. By combining glucose insights from Abbott’s Lingo biowearable with Google’s expertise… read more.
Idorsia Ltd announces that the US Drug Enforcement Administration (DEA) will publish a proposed rule to reclassify dual orexin receptor antagonists (DORAs) from Schedule IV to Schedule V… read more.
NICE: Finerenone can be used, within its marketing authorisation, as an option to treat symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults. Why… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
